Abbott Ordered to Pay $1.67B in Patent Case

"J&J acknowledged at trial that it did not start working on a fully-human antibody until 1997 -- two years after Abbott discovered Humira and one year after Abbott filed its patent applications for Humira," Stoffel added.

Taylor said Centocor will continue to assert intellectual property rights for its immunology therapies.

Shares of J&J closed up 36 cents Monday to $56.96. Abbott shares finished up 39 cents at $47.82, but slipped $1.07, or 2.2%, to $46.75 in after-hours trading.